The pharmaceutical industry faces significant scrutiny from regulators, governments and consumers, under pressure to deliver innovative, life-changing drugs and with demands for increasing transparency and accountability. By automating some of the lengthy, time-consuming and expensive manual reporting needed to ensure compliance and safety, NEXS can save significant time and money, helping get drugs to market faster and safer.
The drug discovery process ends when one lead compound is found for a drug candidate, and the process of drug development starts. Once a lead compound is found, drug development begins with preclinical research to determine the efficacy and safety of the drug.
One of NEXS Research & Development Group’s core business is clinical supply manufacturing and testing. Quality clinical supply manufacturing and testing services have ensured that products are produced and tested under strict batch record, standard operating procedure, and cGMP controls. Manufacturing operations are fully audited after clinical supply manufacturing and testing by the Quality Assurance Team.
Changes in particle size might alter the correlated properties, i.e. shape, surface area, and porosity. This, in turn, can affect bulk properties, product performance, processability, stability, and appearance of the end product. The APIs being developed are increasingly more intricate, smaller particle sizes.
Other drug developers will work with us to support clinical trials. We maintain the highest level safety when it comes to testing, manufacturing and transferring of products.
Covid-19 has shown us that at the heart of open innovation are the sourcing and leveraging of expertise wherever it can be found, and the sharing of knowledge,
Eventually, integrated partnerships will span the entire research and development continuum – from drug discovery through development and commercialization of new therapeutics.
Less than half of Americans trust pharmaceutical companies. In fact, only 42% of respondents say they have any trust in pharma, with a paltry 6% having a great deal. The current tumult surrounding the COVID-19 vaccine is a great example of what happens when there is NOT operational transparency and instead the population is bombarded with mixed messages. NEXS want to change this.
Get the latest news and updates. For upcoming promos and events.
BALTIMORE, March 5, 2021 /PRNewswire/ — NEXS Research & Development Group is proud to announce a major advancement in its efforts to protect frontline medical, research, and
Discoveries in mice don’t always translate to humans, especially in Alzheimer’s disease,” said co-study leader Ana Maria Cuervo, M.D., Ph.D., the Robert and Renée Belfer
Copyright © 2021 NEXS RESEARCH & DEVELOPMENT GROUP, INC. – All Rights Reserved